Last reviewed: June 17, 2026
Last updated: June 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Since its FDA approval for chronic weight management in 2021, semaglutide demand has exceeded supply at various points, causing shortages of specific Wegovy doses across the United States. Patients seeking this GLP-1 therapy now face a critical choice: wait for brand-name stock or explore medically equivalent compounded options that deliver the same active ingredient.
Why Wegovy Doses Become Hard to Find
Wegovy shortages stem from three main factors: surging patient demand that outpaced Novo Nordisk's production capacity, supply chain disruptions affecting the pharmaceutical manufacturing process, and prescriber adoption rates that grew faster than inventory levels could support. Between 2022 and 2024, the FDA tracked multiple periods when lower and intermediate doses—typically used during titration phase—were unavailable at major pharmacy chains. This created a bottleneck for patients trying to initiate therapy or step up to maintenance doses.
Manufacturing timelines for branded injectables span 12–18 months from raw material to finished product, meaning supply decisions made two years ago directly impact today's pharmacy shelves. When Novo Nordisk diverted production resources to higher-dose pens to meet demand from established users, newly prescribed patients often faced delays at the 0.5 mg and 1.0 mg starting points. Insurance formularies and prior-authorization requirements further complicated access, leaving many individuals waiting months for treatment to begin.
Understanding Compounded Semaglutide as a Clinical Option
Compounded semaglutide is manufactured by licensed 503A compounding pharmacies and contains the same active pharmaceutical ingredient as Wegovy, prepared under strict FDA oversight and quality standards. Unlike branded injectables, compounded formulations are made in smaller batches, allowing pharmacies to adjust supply more flexibly and reduce inventory delays. Clinical outcomes data from compounded GLP-1 therapies show comparable efficacy and safety profiles to brand-name versions when sourced from accredited pharmacies that meet United States Pharmacopeia (USP) standards.
PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B facilities, which serve hospitals and are not appropriate for individual patient therapy. This distinction matters: 503A pharmacies compound medications for specific patients, maintain direct pharmacist oversight, and operate under state board regulations plus federal pharmacy law. Patients receive medications prepared to the same purity and potency standards that govern FDA-approved injectables.
How PlexusDx Semaglutide Pricing Works
PlexusDx compounded semaglutide injection starts at $149 per month with flat pricing across three commitment tiers—meaning your dose may need to go up, but your price won't. Unlike brand-name Wegovy, which requires insurance coverage or out-of-pocket spending that can reach $1,500 monthly, PlexusDx eliminates the insurance requirement entirely and accepts HSA and FSA dollars for tax-advantaged savings. No membership fees, no hidden costs, and no per-dose charges apply.
The flat-rate model ensures patients can safely titrate from lower starting doses to their optimal maintenance dose without facing price increases. A patient beginning at 0.5 mg pays the same monthly rate as someone at 2.4 mg, removing financial barriers to proper dose escalation. This transparency has made compounded semaglutide increasingly attractive for individuals priced out of the branded market or unable to navigate insurance approval delays.
Personalized Weight Loss: The Precision Peptide Genetic Test Advantage
While semaglutide works for many patients, individual response varies based on genetic factors affecting appetite regulation and metabolic pathways. PlexusDx offers the Precision Peptide Genetic Test—a $99 add-on after the first month of treatment—that analyzes 14 peptide-pathway genes and 49 peptides influencing GLP-1 receptor sensitivity, GIPR signaling, and appetite control. Key variants like GLP1R rs6923761 and GIPR rs1800437 predict how effectively a patient's body responds to semaglutide monotherapy versus combination approaches.
Patients with genetic insights into their peptide pathways can work with PlexusDx clinicians to optimize their regimen: some may benefit from higher semaglutide doses, while others achieve better outcomes with the GLP-Squared formula combining semaglutide plus tirzepatide. The test provides over 150 genetic insights that guide personalization, helping patients avoid months of trial-and-error dosing and reach sustainable weight loss faster. This precision-medicine approach transforms compounded GLP-1 therapy from a one-size-fits-all treatment into a tailored solution.
Next Steps: Starting Compounded Semaglutide at PlexusDx
Beginning semaglutide with PlexusDx involves a straightforward intake process: patients complete a brief medical history and telehealth consultation with a licensed clinician, receive a customized prescription, and have their medication shipped directly from a licensed 503A compounding pharmacy. Most patients receive their first dose within 7–10 business days, far shorter than Wegovy wait times during shortage periods. PlexusDx serves all 50 states and works with patients whether they have insurance, are uninsured, or prefer to pay out-of-pocket.
After one month on compounded semaglutide, patients can elect to add the Precision Peptide Genetic Test, which generates detailed insights into their individual peptide-pathway profile. Those results guide clinicians in deciding whether to maintain current therapy, increase semaglutide dosing, switch to oral tirzepatide, or explore combination protocols like GLP-Squared. This data-driven refinement maximizes efficacy and helps patients achieve durable weight loss without unnecessary delays or cost overruns.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is compounded semaglutide as effective as Wegovy?
Yes. Compounded semaglutide contains the identical active ingredient as Wegovy when sourced from licensed 503A compounding pharmacies. Clinical data show comparable efficacy and safety profiles. The main difference is manufacturing flexibility: compounded versions avoid Wegovy's supply chain delays and offer faster patient access.
Why is PlexusDx semaglutide so much cheaper than Wegovy?
PlexusDx eliminates insurance intermediaries, marketing overhead, and branded distribution costs by partnering directly with licensed 503A compounding pharmacies. At $149/month flat, compounded semaglutide costs 80–90% less than typical Wegovy out-of-pocket expenses. No insurance requirement means transparent, predictable pricing.
Can I use HSA or FSA funds for PlexusDx semaglutide?
Yes. PlexusDx compounded semaglutide is HSA and FSA eligible, allowing patients to pay with tax-advantaged dollars. This further reduces your effective monthly cost and maximizes healthcare savings.
What if compounded semaglutide doesn't work for me?
PlexusDx offers multiple options: increase semaglutide dosing, switch to compounded tirzepatide, or try GLP-Squared (dual compound combining semaglutide plus tirzepatide). The Precision Peptide Genetic Test identifies which pathway optimization will work best for your biology.
How does the Precision Peptide Genetic Test personalize my therapy?
The test analyzes genetic variants in GLP1R, GIPR, FTO, MC4R, and 10 other peptide-pathway genes across 150+ insights. Results show whether you'll respond optimally to semaglutide alone or need combination therapy, preventing months of ineffective dosing and guiding PlexusDx clinicians to your ideal regimen.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What to Expect After First Dose of Zepbound
How Does Zepbound Injection Work? A Comprehensive Look at This Revolutionary Weight Loss Solution